ERBB2 and breast carcinoma: Thus, our data demonstrated broad changes in the lipid metabolism in aspirin-treated HER-2-positive breast cancer cells with or without Compound C pre-treatment, and that Compound C might be a novel inhibitor of lipid metabolism in HER-2-positive breast cancer cells in combination with aspirin.